Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBT Margin (2016 - 2025)

Historic EBT Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 24.96%.

  • Gyre Therapeutics' EBT Margin rose 95400.0% to 24.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.24%, marking a year-over-year increase of 883400.0%. This contributed to the annual value of 21.95% for FY2024, which is 897900.0% up from last year.
  • Gyre Therapeutics' EBT Margin amounted to 24.96% in Q3 2025, which was up 95400.0% from 8.36% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year EBT Margin high stood at 45.93% for Q1 2024, and its period low was 1830.73% during Q1 2022.
  • Moreover, its 5-year median value for EBT Margin was 8.36% (2025), whereas its average is 424.65%.
  • Its EBT Margin has fluctuated over the past 5 years, first crashed by -15035900bps in 2021, then soared by 18558800bps in 2023.
  • Over the past 5 years, Gyre Therapeutics' EBT Margin (Quarter) stood at 832.34% in 2021, then surged by 97bps to 22.46% in 2022, then crashed by -1544bps to 369.38% in 2023, then surged by 101bps to 2.77% in 2024, then skyrocketed by 801bps to 24.96% in 2025.
  • Its last three reported values are 24.96% in Q3 2025, 8.36% for Q2 2025, and 21.01% during Q1 2025.